Comprehensive Analysis Reveals the Potential Roles of CDKN3 in Pancancer and Verification in Endometrial Cancer

Overview

Journal Int J Gen Med

Publisher Dove Medical Press

Specialty General Medicine

Date 2023 Dec 18

PMID 38106976

Authors

Chao Gao

Xiangqin Fan

Yanyan Liu

Yanyan Han

Shiqi Liu

Huanrong Li

Qiaoling Zhang

Yingmei Wang

Fengxia Xue

Affiliations

Soon will be listed here.

Abstract

Background: Cyclin-dependent kinase inhibitor 3 (CDKN3) has been studied in many cancers. However, the comprehensive and systematic pancancer analysis of CDKN3 genes is still lacking.

Methods: Data were downloaded from online databases. R was used for analysis of the differential expression and gene alteration of CDKN3 and of the associations between CDKN3 expression and survival, signaling pathways, and drug sensitivity. Clinical samples and in vitro experiments were selected for verification.

Results: CDKN3 expression was higher in most types of cancers, and this phenotype was significantly correlated with poor survival. CDKN3 showed gene alterations and copy number alterations in many cancers and associated with some immune-related pathways and factors. Drug sensitivity analysis elucidated that CDKN3 could be a useful marker for therapy selection. Clinical samples elucidated CDKN3 expressed high in endometrial cancer tissue. In vitro studies showed that CDKN3 induced pro-tumor effect in immune environment and facilitated endometrial cancer cell proliferation and G1/S phase transition.

Conclusion: CDKN3 has been shown to be highly expressed in most types of cancers and promoted cancer cell progression. CDKN3 may serve as a novel marker in clinical diagnosis, treatment, and prognosis prediction in future.

Citing Articles

The role of Cyclin Dependent Kinase Inhibitor 3 () in promoting human tumors: Literature review and pan-cancer analysis.

Zhang C, Shen Q, Gao M, Li J, Pang B Heliyon. 2024; 10(4):e26061.

PMID: 38380029 PMC: 10877342. DOI: 10.1016/j.heliyon.2024.e26061.

References

Abdel-Tawab M, Fouad H, Othman A, Eid R, Mohammed M, Hassan A . Evaluation of gene expression of PLEKHS1, AADAC, and CDKN3 as novel genomic markers in gastric carcinoma. PLoS One. 2022; 17(4):e0265184. PMC: 9022821. DOI: 10.1371/journal.pone.0265184. View

Chen C, Feng X, Liao H, Jin W, Zhang J, Wang Y . Regulation of T cell proliferation by JMJD6 and PDGF-BB during chronic hepatitis B infection. Sci Rep. 2014; 4:6359. PMC: 4163673. DOI: 10.1038/srep06359. View

Iriuchijima N, Sato-Harada R, Takano M, Fujio K, Sato T, Goto F . Reduced expression of kinase-associated phosphatase in cortical dendrites of MAP2-deficient mice. Biochem Biophys Res Commun. 2005; 338(2):1216-21. DOI: 10.1016/j.bbrc.2005.10.077. View

Li W, Zhang L, Wu Y . CDKN3 regulates cisplatin resistance to colorectal cancer through TIPE1. Eur Rev Med Pharmacol Sci. 2020; 24(7):3614-3623. DOI: 10.26355/eurrev_202004_20823. View

Yang C, Chen L, Niu Q, Ge Q, Zhang J, Tao J . Identification and validation of an E2F-related gene signature for predicting recurrence-free survival in human prostate cancer. Cancer Cell Int. 2022; 22(1):382. PMC: 9721026. DOI: 10.1186/s12935-022-02791-9. View

Song H, HANLON N, Brown N, Noble M, Johnson L, Barford D . Phosphoprotein-protein interactions revealed by the crystal structure of kinase-associated phosphatase in complex with phosphoCDK2. Mol Cell. 2001; 7(3):615-26. DOI: 10.1016/s1097-2765(01)00208-8. View

Qian X, Zhang J, Mai Y, Yin X, Zheng Y, Yu Z . A Novel Insight into Paraptosis-Related Classification and Signature in Lower-Grade Gliomas. Int J Genomics. 2022; 2022:6465760. PMC: 9678488. DOI: 10.1155/2022/6465760. View

Zhang M, Wang X, Yao J, Qiu Z . Long non-coding RNA NEAT1 inhibits oxidative stress-induced vascular endothelial cell injury by activating the miR-181d-5p/CDKN3 axis. Artif Cells Nanomed Biotechnol. 2019; 47(1):3129-3137. DOI: 10.1080/21691401.2019.1646264. View

Ma Z, Liu Y, Hao Z, Hua X, Li W . DNA hypermethylation of aurora kinase A in hepatitis C virus‑positive hepatocellular carcinoma. Mol Med Rep. 2019; 20(3):2519-2532. PMC: 6691273. DOI: 10.3892/mmr.2019.10487. View

10.

Dogan Sigva Z, Balci Okcanoglu T, Biray Avci C, Yilmaz Susluer S, Kayabasi C, Turna B . Investigation of the synergistic effects of paclitaxel and herbal substances and endemic plant extracts on cell cycle and apoptosis signal pathways in prostate cancer cell lines. Gene. 2018; 687:261-271. DOI: 10.1016/j.gene.2018.11.049. View

11.

Fauman E, Saper M . Structure and function of the protein tyrosine phosphatases. Trends Biochem Sci. 1996; 21(11):413-7. DOI: 10.1016/s0968-0004(96)10059-1. View

12.

Liu D, Zhang J, Wu Y, Shi G, Yuan H, Lu Z . YY1 suppresses proliferation and migration of pancreatic ductal adenocarcinoma by regulating the CDKN3/MdM2/P53/P21 signaling pathway. Int J Cancer. 2017; 142(7):1392-1404. DOI: 10.1002/ijc.31173. View

13.

Poon R, Hunter T . Dephosphorylation of Cdk2 Thr160 by the cyclin-dependent kinase-interacting phosphatase KAP in the absence of cyclin. Science. 1995; 270(5233):90-3. DOI: 10.1126/science.270.5233.90. View

14.

Yang B, Luo L, Luo W, Zhou Y, Yang C, Xiong T . The genomic dynamics during progression of lung adenocarcinomas. J Hum Genet. 2017; 62(8):783-788. PMC: 5537414. DOI: 10.1038/jhg.2017.40. View

15.

Dangi A, Husain I, Jordan C, Yu S, Natesh N, Shen X . Blocking CCL8-CCR8-Mediated Early Allograft Inflammation Improves Kidney Transplant Function. J Am Soc Nephrol. 2022; 33(10):1876-1890. PMC: 9528333. DOI: 10.1681/ASN.2022020139. View

16.

Deng M, Wang J, Chen Y, Zhang L, Xie G, Liu Q . Silencing cyclin-dependent kinase inhibitor 3 inhibits the migration of breast cancer cell lines. Mol Med Rep. 2016; 14(2):1523-30. PMC: 4940103. DOI: 10.3892/mmr.2016.5401. View

17.

Turpaev K, Glatigny A, Bignon J, Delacroix H, Drapier J . Variation in gene expression profiles of human monocytic U937 cells exposed to various fluxes of nitric oxide. Free Radic Biol Med. 2009; 48(2):298-305. DOI: 10.1016/j.freeradbiomed.2009.10.054. View

18.

Wang H, Chen H, Zhou H, Yu W, Lu Z . Cyclin-Dependent Kinase Inhibitor 3 Promotes Cancer Cell Proliferation and Tumorigenesis in Nasopharyngeal Carcinoma by Targeting p27. Oncol Res. 2017; 25(9):1431-1440. PMC: 7840971. DOI: 10.3727/096504017X14835311718295. View

19.

Chang T, Chen C, Chen J . CCL7 as a novel inflammatory mediator in cardiovascular disease, diabetes mellitus, and kidney disease. Cardiovasc Diabetol. 2022; 21(1):185. PMC: 9479413. DOI: 10.1186/s12933-022-01626-1. View

20.

Lee S, Reimer C, Fang L, Iruela-Arispe M, Aaronson S . Overexpression of kinase-associated phosphatase (KAP) in breast and prostate cancer and inhibition of the transformed phenotype by antisense KAP expression. Mol Cell Biol. 2000; 20(5):1723-32. PMC: 85355. DOI: 10.1128/MCB.20.5.1723-1732.2000. View